China Healthcare:Data Update,Introducing interim estimates

We have introduced 1H17 and 2H17 estimates for 3SBio, CMS, Weigao,and Sinopharm. Further, we have introduced quarterly estimates forNHWA Pharma. We do not view these changes as material, and there is nochange to our investment theses, ratings or price targets (summarized inExhibit 1).